Methcathinone self-administration decreases dopamine and serotonin transporter function in rats

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• Methcathinone (MCAT) is a synthetic cathinone with high misuse potential.
• It exerts stimulant effects by acting on monoaminergic transporters like dopamine and serotonin transporters.
• Previous studies focused on direct drug effects, not self-administration impacts.

Purpose of the Study:

• To investigate the acute effects of methcathinone self-administration on striatal dopamine and hippocampal serotonin transporter function.
• To determine if self-administration models differ from investigator-administered or in vitro exposure.
• To establish a rodent model for studying MCAT's neurochemical effects.

Main Methods:

• Adult male Sprague Dawley rats underwent 7 days of methcathinone self-administration (FR1, 240 min/session, 0.18 mg/10 μl infusion).
• Control rats received saline infusions.
• [3H]Monoamine uptake was measured 1 hour after the final self-administration session.

Main Results:

• Rats readily self-administered methcathinone.
• Methcathinone self-administration rapidly decreased striatal dopamine transporter (DAT) function.
• Methcathinone self-administration rapidly decreased hippocampal serotonin transporter (SERT) function.

Conclusions:

• Methcathinone self-administration significantly impacts DAT and SERT function.
• This finding supports MCAT's high misuse liability.
• Rodent self-administration provides a valuable model for understanding MCAT's neurochemical mechanisms.